NHSA response to Northern Powerhouse Partnership report

The Northern Health Science Alliance responds to Northern Powerhouse Partnership report

3rd February 2017

Response to the Northern Powerhouse Partnership report:

Responding to the Northern Powerhouse Partnership report issued today, Chief Executive of the Northern Health Science Alliance Dr Hakim Yadi OBE said:

“The Northern Health Science Alliance welcomes the Northern Powerhouse Partnership report in particular its recognition of health innovation as a prime capability for the North. The north is at the forefront of health innovation delivering more clinical trials than Cambridge – London and Oxford combined and also home to the world-first real world clinical trials – the Salford Lung Study.

“The NHSA has been working across the North in Health Innovation for the past five years and has established a new model of working between the North’s great cities in health innovation. 

“Last year we worked with IPPR North to review the scale and potential of the North’s health innovation economy, our report, Health Innovation: Breathing Life into the Northern Powerhouse demonstrated health and life science accounts for £17.5 billion of the North’s £305 billion output (GVA) and is forecast to grow by 44.6% by 2030. The sector employs over 570,000 people with over 38,000 employed in highly skilled private sector positions alone. 

“Frustratingly, while the North receives 20% of UK private sector funding for health and life sciences, it receives less than 6% of UK public sector spend.

“The ‘Health Innovation: Breathing Life into the Northern Powerhouse’ report made a number of recommendations for a place-based approach to industrial strategy for the health science sector and for  catch-up capital for research funding to bring the North in line with the rest of the country.

“I am looking forward to working with the Northern Powerhouse Partnership on delivering a health innovation agenda for the Powerhouse.”


Media Contact

For more information, contact,


Subscribe to our Newsletter